Amid Shifting Fortunes, BioNTech Bets on a Cancer Breakthrough
BioNTech faces financial challenges as COVID-19 vaccine demand wanes, with earnings dropping from €3.83 per share to a €2.77 loss and revenues from €3.82 billion to €2.75 billion. The company…